HEDTUMSO Trademark

Trademark Overview


On Monday, August 2, 2021, a trademark application was filed for HEDTUMSO with the United States Patent and Trademark Office. The USPTO has given the HEDTUMSO trademark a serial number of 90860790. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by Bristol-Myers Squibb Company. The HEDTUMSO trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, namely t cell therapy; phar...
hedtumso

General Information


Serial Number90860790
Word MarkHEDTUMSO
Filing DateMonday, August 2, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 17, 2023

Trademark Statements


Goods and Servicespharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, namely t cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical use; pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 8, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Tuesday, April 26, 2022NON-FINAL ACTION E-MAILED
Thursday, August 5, 2021NEW APPLICATION ENTERED
Tuesday, September 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 19, 2022ASSIGNED TO EXAMINER
Tuesday, April 26, 2022NON-FINAL ACTION WRITTEN
Tuesday, April 26, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 25, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 25, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 25, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 8, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, December 8, 2022EXAMINERS AMENDMENT E-MAILED
Thursday, December 8, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, December 8, 2022EXAMINER'S AMENDMENT ENTERED
Monday, December 12, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 14, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 29, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 29, 2023SOU EXTENSION 1 FILED
Tuesday, August 29, 2023SOU EXTENSION 1 GRANTED
Tuesday, August 29, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 8, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, September 8, 2023ITU LETTER MAILED, NO RESPONSE REQUIRED
Wednesday, February 7, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 3 FILED
Tuesday, August 27, 2024SOU EXTENSION 3 GRANTED
Friday, February 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 7, 2024SOU EXTENSION 2 FILED
Wednesday, February 7, 2024SOU EXTENSION 2 GRANTED